Royalty Pharma (RPRX) Debt to Equity (2019 - 2026)

Royalty Pharma has disclosed Debt to Equity across 8 years of filings, most recently posting $0.9 for Q1 2026.

• Debt to Equity for Q1 2026 came in at $0.9, up 15.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.9 (up 15.69% YoY), and the FY2025 annual result was $0.92, up 25.18% from the prior year.
• Debt to Equity came in at $0.9 for Q1 2026 at Royalty Pharma, down from $0.92 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.93 in Q3 2025 to a low of $0.6 in Q3 2022.
• The 5-year median for Debt to Equity is $0.74 (2024), against an average of $0.74.
• Across the five-year window, Debt to Equity retreated 18.56% in 2023 and increased 25.39% in 2025, its largest moves.
• Royalty Pharma's Debt to Equity stood at $0.75 in 2022, then decreased by 18.56% to $0.61 in 2023, then grew by 20.98% to $0.74 in 2024, then advanced by 25.18% to $0.92 in 2025, then dropped by 2.17% to $0.9 in 2026.
• The last three Debt to Equity figures came in at $0.9 (Q1 2026), $0.92 (Q4 2025), and $0.93 (Q3 2025), per Business Quant data.